Article

Preliminary evidence shows ranibizumab benefit in DME

Las Vegas-A pilot study of ranibizumab (Lucentis, Genentech), a vascular endothelial growth factor (VEGF) antagonist, showed that the drug has a biological effect in diabetic macular edema (DME), reported Peter Campochiaro, MD, who spoke at the American Academy of Ophthalmology annual meeting.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Study examines efficiency of physiotherapy in treating, preventing uncomplicated acquired myopia
November 26th 2024

Study examines efficiency of physiotherapy in treating, preventing uncomplicated acquired myopia

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study finds low incidence of microbial keratitis with overnight ortho-k lenses
November 25th 2024

Study finds low incidence of microbial keratitis with overnight ortho-k lenses

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

OCTA reveals retinal vascular damage in patients diagnosed with renal hypertension, offers early diagnostic insights
November 25th 2024

OCTA reveals retinal vascular damage in patients diagnosed with renal hypertension, offers early diagnostic insights

Next-generation sequencing in ocular oncology brings advances in diagnosis, management
November 25th 2024

Next-generation sequencing in ocular oncology brings advances in diagnosis, management

© 2024 MJH Life Sciences

All rights reserved.